AstraZeneca, Oxford University resume clinical trials of Covid-19 vaccine

Clinical trials of COVID-19 vaccine being developed by AstraZeneca and Oxford University have resumed in the United Kingdom after a brief safety pause. The trials resumed after the Medicines Health Regulatory Authority confirmed that the trials are safe. AstraZeneca had paused its trials on Tuesday after observing a single event of an unexplained illness that occurred in the UK phase III



trial.

After Astrazeneca resumed the trial in the United Kingdom, Serum Institute of India has said that they will restart the trial in the country once the apex drug regulator allows. Serum Institute of India partnered with AstraZeneca to manufacture the Oxford COVID-19 vaccine candidate for low-and-middle income countries.